Table 2 Clinical outcomes*
From: Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial
Control (N = 15) | CytoSorb (N = 15) | |
|---|---|---|
Outcome | ||
Re-operation within 48 h—no. (%) | 1 (6.7) | 0 (0) |
Post-operative extracorporeal membrane oxygenation—no. (%) | 0 (0) | 1 (6.7) |
Post-operative intra-aortic balloon pump—no. (%) | 0 (0) | 0 (0) |
Vasoconstrictors | ||
Need for any vasoconstrictor—no. (%) | 13 (86.7) | 14 (93.3) |
Median noradrenaline dose post-operative day 1—(IQR) μg/min | 4.8 (2.0–13.7) | 5.6 (1.5–6.8) |
Median noradrenaline dose post-operative ICU stay—(IQR) μg/min | 4.3 (2.0–7.8) | 4.7 (1.5–7.1) |
Inotropes | ||
Need for any inotrope—no. (%) | 12 (80.0) | 10 (66.7) |
Median dobutamine dose post-operative day 1—(IQR) μg/min | 0 (0) | 0 (0–162) |
Median dobutamine dose post-operative ICU Stay—(IQR) μg/min | 0 (0–103) | 0 (0–141) |
Fluid balance at 24 h ICU—(IQR) ml | 2240 (400–3589) | 3000 (2000–4250) |
Diuresis 24 h ICU—(IQR) ml | 1125 (895–1700) | 1495 (970–1930) |
Mechanical ventilation—(IQR) hours | 8 (2–102) | 5 (0–16) |
Acute kidney injury—no. (%)† | 4 (26.7) | 4 (26.7) |
Post-operative need for renal replacement therapy—no. (%) | 1 (6.7) | 0 (0) |
Renal replacement therapy dependence on hospital discharge—no. (%) | 1 (6.7) | 0 (0) |
Serum creatinine on ICU discharge—(IQR) μmol/l | 78 (65–126) | 73 (68–103) |
Serum creatinine on hospital discharge—(IQR) μmol/l | 87 (72–120) | 78 (68–97) |
ICU length of stay—(IQR) days | 1.0 (0.9–8.9) | 1.8 (0.9–2.0) |
Hospital length of stay—(IQR) days | 12.0 (11.0–17.0) | 12.5 (6.0–19.0) |
ICU readmission—no. (%) | 1 (7.7) | 2 (13.3) |
ICU mortality—no. (%) | 2 (13.3) | 1 (6.7) |
Hospital mortality—no. (%) | 2 (13.3) | 1 (6.7) |